Biosimilars: Some Patient And Prescriber Groups Appear To Warm Up To Arbitrary Suffixes
Executive Summary
Patient and prescriber groups were largely opposed to suffixes for the nonproprietary names of biological products being devoid of meaning when the US FDA first published its nomenclature policy, although a few of these groups may be signaling less of a worry than they once had.
You may also be interested in...
FDA Warns Over Denigrating Biosimilars
The guidance states that promotion creating an impression that differences are clinically meaningful when the US FDA has said they are not could be judged misleading.
Biosimilar Information Wars: Draft Guidance Seeks To Clamp Down On Efforts To Hinder Uptake In The US
The guidance states that promotion creating an impression that differences are clinically meaningful when the US FDA has said they are not could be judged misleading.
Woodcock: Concerns About US FDA's Biosimilars Suffix Policy Detached From Reality
In an exclusive interview, Center for Drug Evaluation and Research Director Janet Woodcock contends that industry concerns about FDA's new suffix policy aren't reflective of real-world problems.